Britain defends investment record as Merck scraps labs over pharma environment

U.S. drugmaker Merck has abandoned its planned London research center, citing the UK's lack of progress in addressing underinvestment and undervaluation of innovative medicines, a decision that follows AstraZeneca's earlier withdrawal of a UK vaccine plant project. This move underscores a challenging investment climate for the British life sciences sector, with the Association of the British Pharmaceutical Industry noting the UK's foreign direct investment ranking in the sector has fallen from second in 2017 to seventh in 2023, signaling growing reluctance for pharmaceutical investment amid ongoing government disputes and external pressures.

Analysis

Merck's (MRK.N) decision to abandon its planned London research center represents a significant blow to the UK's life sciences ambitions and signals a deteriorating investment climate. This is not an isolated incident, as it follows AstraZeneca's (AZN.L) cancellation of a £450 million UK vaccine plant earlier in the year. Merck explicitly cited the UK government's failure to address chronic underinvestment and the "undervaluation of innovative medicines" as primary drivers for its withdrawal. The broader industry sentiment is sharply negative, evidenced by the Association of the British Pharmaceutical Industry's report that the UK's foreign direct investment ranking in the sector has plummeted from second in 2017 to seventh in 2023. Compounding these domestic policy issues, which include unresolved disputes over NHS drug pricing, are external pressures such as potential U.S. tariffs and a political push for manufacturing to return to the United States. While the UK government cited a £520 million fund and a favorable Deloitte survey, the actions of major pharmaceutical firms suggest these measures are insufficient to counteract the negative headwinds.

Key Decisions for Investors

• Investors should scrutinize the UK exposure of pharmaceutical companies like AstraZeneca (AZN.L) and GSK (GSK.L), as the escalating policy and investment risks could create headwinds for their domestic profitability and growth.
• Merck's withdrawal should be seen as a leading indicator of capital reallocation away from the UK; monitor for similar strategic pivots from other multinational corporations, which would confirm a systemic de-risking from the UK life sciences sector.
• For Merck (MRK.N) investors, the decision, while reflecting negatively on the UK, could be viewed as prudent capital discipline, redirecting investment toward jurisdictions with more favorable government policies and potentially higher returns.
• Closely monitor the outcome of the UK's drug pricing negotiations with the pharmaceutical industry and any U.S.-UK trade developments, as these are key catalysts that will dictate the sector's future investment viability.